EP Patent

EP2016075A1 — Thiazole derivatives and their use as anti-tumour agents

Assigned to AstraZeneca AB · Expires 2009-01-21 · 17y expired

What this patent protects

The invention concerns thiazole derivatives of Formula (I) or pharmaceutically-acceptable salts thereof, wherein each of R, Ring A, m, R1, R2 and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions conta…

USPTO Abstract

The invention concerns thiazole derivatives of Formula (I) or pharmaceutically-acceptable salts thereof, wherein each of R, Ring A, m, R1, R2 and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.

Drugs covered by this patent

Patent Metadata

Patent number
EP2016075A1
Jurisdiction
EP
Classification
—
Expires
2009-01-21
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.